Beigel, John H.

Remdesivir for the Treatment of Covid-19 — Final Report

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 7,267

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 3,237

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 1,523

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 722

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 673

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 153

Licensed H5N1 vaccines generate cross-neutralizing antibodies against highly pathogenic H5N1 clade 2.3.4.4b influenza virus

Khurana, S., King, L. R., Manischewitz, J., Posadas, O., Mishra, A. K., Liu, D., Beigel, J. H., Rappuoli, R., Tsang, J. S., & Golding, H. (2024) · Nature Medicine

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 57

Toward Better Clinical Data in Emerging Infectious Diseases

Beigel, J. H. (2009) · Clinical Infectious Diseases

Viral Infections and Outbreaks ResearchCOVID-19 Clinical Research Studies

Cited by 3